Beijing Konruns Pharmaceutical Co (SHSE:603590) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603590 Beijing Konruns Pharmaceutical Co Ltd SHSE:603590
79 GF Score
Price ¥29.88
GF Value ¥33.42
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Beijing Konruns Pharmaceutical Co Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Beijing Konruns Pharmaceutical Co Quality Rank Related Terms

SHSE:603590
79GF Score
Beijing Konruns Pharmaceutical Co Ltd SHSE:603590
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Beijing Konruns Pharmaceutical Co (SHSE:603590) Overvalued in 2026?

Based on GuruFocus' analysis, Beijing Konruns Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥29.88 is trading 10.6% below its estimated GF Value™ of ¥33.42. GuruFocus considers Beijing Konruns Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:603590:

  • Quality Rank:
  • GF Value™: ¥33.42 vs. price of ¥29.88 (10.6% below fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603590 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Beijing Konruns Pharmaceutical Co Business Description

Address Building 3, No. 7 Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
Beijing Konruns Pharmaceutical Co Ltd is a Chinese pharmaceutical company. It is engaged in the research and development of inventive drugs, and is oriented to clinical needs.
79GF Score

Get the complete analysis for SHSE:603590

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥29.88
Price
¥33.42
GF Value